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ABSTRACT 44 
 Metal implants are used routinely during total hip and knee replacements and are typically 45 
composed of cobalt chromium molybdenum (CoCrMo) alloys&R&U0R³ZHDUSDUWLFOHV´LQWKH46 
nano- and micro-size ranges, are generated in situ. Meanwhile, occupational exposure to CoCrMo 47 
particles may be associated with the development of industrial GHQWDOZRUNHU¶VSQHXPRFRQLRVLV. 48 
In this study, we report that both nano- and micro-CoCrMo particles induced a time and dose-49 
dependent toxicity in various cell types (i.e. lung epithelial cells, osteoblasts, and macrophages), 50 
and the effects of particle size on cell viability and oxidative responses were interesting and cell 51 
specific. Our findings highlight the potential roles that nano- and micro-CoCrMo particles, 52 
whether exposure is due to inhalation or implant wear, and associated oxidative stress may play in 53 
the increasingly reported implant loosening, osteolysis, and systemic complications in orthopaedic 54 
patients, and may explain the risk of lung diseases in dental workers. 55 
 56 
Keywords: Nanoparticle, implant wear, toxicity, oxidative stress, cobalt chromium molybdenum 57 
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1. Introduction  58 
 Over a million total hip replacement procedures are performed each year and cobalt 59 
chromium molybdenum (CoCrMo) alloys have been widely used as metal-on-metal or metal-on-60 
polyethylene implant devices. While metal implant devices offer advantages, such as high strength, 61 
evidence emerges that metal (e.g. CoCrMo) implant devices may generate wear particles in situ, 62 
within the micro- and nano-size range, as a result of implant breakdown between the articulating 63 
joint surfaces.1, 2 The generation of wear particles increases when the implant is improperly 64 
aligned, causing aseptic loosening of the joint, uneven wear and damage within the implant area.2, 65 
3
 The specific role of CoCrMo particles in joint loosening or associated osteolysis remains unclear, 66 
although several sources suggest that the presence of wear particles within the joint cavity 67 
promotes a localized inflammatory response succeeded by resorptive bone loss.4-7 Given this 68 
evidence and emerging concerns regarding the long term effects of CoCrMo particle exposure in 69 
joint replacement patients, the toxicity of CoCrMo wear particles has recently gained great 70 
interests both in vitro 8-12 and in vivo.13-15 71 
In addition to ³LQWHUQDO´ and localized CoCrMo particle exposure due to implant wear, 72 
alternative routes of exposure such as inhalation or secondary exposure(s) due to particle 73 
translocation or migration from the initial site must be considered. For instance, CoCrMo particle 74 
inhalation may occur during the manufacturing and production in the medical device industry, 75 
thereby presenting an occupational exposure hazard. Although occupational exposure to CoCrMo 76 
particles has not been directly reported to date in orthopaedic implant manufacturing settings, 77 
SXOPRQDU\H[SRVXUHWR&R&U0R³GXVWV´ZLWKDVLPLODUFRPSRVLWLRQto metal orthopaedic implant 78 
material have been reported previously in dental implant manufacturing settings.16 Inhalation of 79 
CoCrMo particles might have been associated with the ³GHQWDO WHFKQLFLDQ¶V SQHXPRFRQLRVLV´80 
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(DTP) in a number of cases.17 In other industrial and manufacturing settings, inhalation of cobalt-81 
FRQWDLQLQJPHWDO ³GXVWV´, such as tungsten carbide cobalt (WC-Co), have been well-associated 82 
with the development of pneumoconiosis, occupational asthma and lung disease with increased 83 
risk of lung cancer.18, 19 For DTP resulting from exposure to CoCrMo particles, patients develop 84 
lung disease with a similar clinical presentation to hard metal lung disease (HMLD) resulting from 85 
occupational inhalation of WC-Co particles; 3, 17, 20 therefore, we believe it is pertinent to examine 86 
the effects of CoCrMo particle exposure in a relevant in vitro pulmonary model. 87 
There is also emerging evidence that particles within the nano-size range are capable of 88 
tissue translocation and migration to other organs, such as the liver, spleen or lungs,21-23 where 89 
tissue deposition occurs and a secondary particle exposure is generated. This phenomenon may 90 
occur for CoCrMo particles generated internally at orthopaedic implant sites and the potential for 91 
secondary CoCrMo toxicity at sites distant from the initial exposure cannot be excluded. 92 
Therefore, it is critically important to understand the full range of effects of CoCrMo particle 93 
exposure on a variety of cell types which are potential targets for CoCrMo particle exposure, 94 
whether the initial exposure was due to internal particle generation from orthopaedic implants or 95 
from external sources such as inhalation in occupational settings. The goal of the current study 96 
was to examine the toxicity and oxidative stress response induced by nano- and micro-sized 97 
CoCrMo particles in various cell types using a nanotoxicity model recently developed in our lab.24 98 
We hypothesized that nano- and micro-CoCrMo particles would exert cell-specific, time and dose-99 
dependent toxicity and oxidative stress response in lung epithelial cells, osteoblasts, and 100 
macrophages. 101 
 102 
2.  Methods 103 
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2.1. Materials and Reagents: CoCrMo microparticles (micro-CoCrMo) in the form of gas 104 
atomized powders from ASTM75 implants were used as received from Sandvik Osprey 105 
(Sandviken, Sweden); the chemical composition was 63.3r1.1 wt.% Co, 30.2r0.7 wt.% Cr and 106 
6.5r1.2 wt.% Mo. Human lung bronchial epithelial BEAS-2B cells,24 THP-1 (TIB-202) human 107 
monocyte/macrophage25 and h.FOB1.19 (CRL-11372) human osteoblast cells26-29 from our 108 
previous studies were from American Type Tissue Collection (ATCC; Manassas, VA'XOEHFFR¶V109 
0RGLILHG(DJOH0HGLD'0(0+DP¶V)0HGLXPVWHULOHSKRVSKDWHEXIIHUHGVDOLQH3%6110 
0.25% trypsin/ethylenediaminetetraacetic acid (EDTA), fetal bovine serum (FBS), G418 sulfate 111 
(geneticin) cell selection agent and penicillin/streptomycin were purchased from Lonza (Allendale, 112 
NJ). RPMI-1640 culture medium was purchased from ATCC. Isopropanol, hydrochloric acid, 113 
Triton-X-100, thiazolyl blue tetrazolinium bromide (MTT reagent), ¶¶-dichlorofluorescein 114 
diacetate (DCF), dihydroethidium (DHE) and phorbol-12-mystirate-13-acetate (PMA) were 115 
purchased from Sigma-Aldrich (St. Louis, MO).  116 
2.2.  Particle Preparation and Characterization: CoCrMo nanoparticles (nano-CoCrMo) were 117 
obtained via mechanical milling of the micro-CoCrMo particles (see Supplemental Materials). 118 
Dilute particle suspensions, ranging from 0.1 to 1000 ȝg/mL, were prepared in DMEM containing 119 
10% FBS and used immediately on the day of each experiment. The particle size of nano-CoCrMo 120 
was analyzed using transmission electron microscopy (TEM). Average particle size was achieved 121 
by measuring Feret diameter of ca. 300 particles, which is defined as the distance between the 122 
most widely spaced nanoparticles in an agglomerate.30 The particle size of micro-CoCrMo 123 
particles was characterized using scanning electron microscope (SEM). In addition, the average 124 
sizes of nano- and micro-CoCrMo particles in suspension in 10% FBS were determined using 125 
dynamic light scattering (DLS, Malvern Zetasizer version 7.01, Malvern Instruments). The 126 
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CoCrMo particles had a zeta potential of -25 mV and showed negligible aggregations in 127 
suspension in short time periods (e.g. 24 hr).31 128 
2.3.  Cell Culture and THP-1 Macrophage Differentiation: THP-1 monocytes were maintained 129 
in suspension culture and upon confluency, THP-1 cells were transferred and centrifuged to pellet. 130 
The cell pellet was re-suspended in RPMI containing PMA which induces THP-1 monocytes to 131 
undergo macrophage (M0) differentiation, and plated in a 96-well culture plate. More details of 132 
the cell culture of BEAS-2B, osteoblasts (OB), and macrophages (M0) are provided in the 133 
Supplemental Materials. 134 
2.4.  CoCrMo Particle Assay Interference: Prior to execution of the cell viability and oxidative 135 
stress assays, the potential interference of CoCrMo particles was examined under the experimental 136 
conditions (see Supplemental Materials).  137 
2.5.  CoCrMo Particle Exposure: Exposure to nano- and micro-CoCrMo particles was achieved 138 
by aspirating the media from each well and immediately replacing it with an equivalent volume of 139 
CoCrMo particle suspension at a concentration of 0.1-1000 ȝJP/. Cell plates were then incubated 140 
at 37° C and 5% CO2 for exposure periods of 6, 12, 24 and 48 hr.  141 
2.6.  Cell Viability Assay: For the viability assay, cells were exposed to either nano- or micro-142 
CoCrMo particles at concentrations of 0.1, 1, 10, 100 and 1000 ȝg/mL for exposure periods of 6, 143 
12, 24 and 48 hr. Following particle treatment, cells were rinsed once with sterile PBS to remove 144 
traces of media and excess particles. Then, ȝ/of un-supplemented DMEM was added to each 145 
ZHOOIROORZHGE\WKHDGGLWLRQRIȝ/077UHDJHQW to achieve a final concentration of 0.5 mg/mL 146 
MTT reagent per well. Cells were incubated for 2 hr at 37° C and 5% CO2 to allow conversion of 147 
the soluble salt (yellow) to formazan crystals (purple). Crystal formation was confirmed using light 148 
microscopy. 1ȝ/RIVROXELOL]DWLRQVROXWLRQ0+&OLQLVRSURSDQROZLWK7ULWRQ-X) was 149 
7 
 
then added to each well to dissolve the formazan crystals and the absorbance of each well was 150 
recorded at 570 nm using a Bio-7HNȝ4XDQWPLFURSODWHUHDGHU:LQRRVNL97%ODQk values were 151 
subtracted from absorbance readings. Cell viability was calculated by dividing the absorbance of 152 
particle treated cells by the absorbance of control cells receiving media treatment only and 153 
converted to percentage; control cells represented 100% viability. 154 
2.7.  Oxidative Stress Assay: Oxidative stress was examined at the same CoCrMo particle 155 
concentrations and exposure range described for the viability assay (above). Following particle 156 
treatment, cells were rinsed once with sterile PBS to remove traces of media and excess particles. 157 
2[LGDWLYHVWUHVVZDVWKHQGHWHUPLQHGE\WKHDGGLWLRQRIȝ0'&)RU'+(LQ3%6IROORZLQJ158 
particle treatment. Plates were incubated for 15 min in the dark and then fluorescence intensity of 159 
each well was quantified at 520 nm for DCF or 620 nm for DHE using a Bio-Tek Synergy H4 160 
plate reader (Winooski, VT). The relative fluorescence of particle-treated cells was calculated as 161 
fold over control.  162 
2.8.  Statistical Analyses: All experiments were performed in triplicate and data are presented as 163 
mean ± standard deviation. Statistical analysis was carried out by two-way analysis of variance 164 
(ANOVA) using GraphPad Prism 6 software (La Jolla, CA). P values < 0.05 were considered 165 
significant.  166 
 167 
3.  Results 168 
3.1.  CoCrMo Particle Characterization and Assay Interference: TEM and SEM examinations 169 
showed that the nano- and micro-CoCrMo particles had average sizes of 35.4 ± 30.4 nm (Figures. 170 
1A and C) and 4.8 ± 3.0  ȝPFigures 1B and D), respectively. DLS analysis indicated that nano-171 
CoCrMo averaged 54 nm and micro-CoCrMo particles averaged ȝP in suspensions. EDX 172 
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confirmed that the composition of nano- and micro-CoCrMo particles were largely Co, Cr and Mo 173 
(Figure S1). We did not find any significant CoCrMo particle interference in our assays; no 174 
significant auto-reduction of the MTT dye was identified in the viability assay (Figure S2) and no 175 
significant changes in DCF/DHE fluorescence were observed due to CoCrMo particles under the 176 
assay conditions tested (Figure S3).  177 
3.2.  CoCrMo Effects on Cell Viability: BEAS-2B, OB and macrophages were exposed to nano- 178 
and micro-CoCrMo particles DWFRQFHQWUDWLRQVRIDQGȝJP/IRUGXUDWLRQVRI179 
6, 12, 24 and 48 hr. For BEAS-2B, the average cell viability was about 90-98% (vs. control of 180 
100%) for cells exposed to nano- and micro-CoCrMo particles at concentrations of 0.1, 1 and 10 181 
ȝJP/ IRU GXUDWLRQV RI -48 hr; the cell viability tended to decrease with increasing particle 182 
exposure WLPHIURPKUWRKUDWFRQFHQWUDWLRQVRIERWKDQGȝJP/Figure 2). In 183 
cells exposed to nano-CoCrMo particles (Figure 2A), a significant reduction in viability 184 
(compared to control) was observed at ȝJP/DIWHUDQGKURIH[SRVXUHDQGDWthe 185 
highest concentration of  ȝJP/ after 6-48 hr of exposure. Similarly, in BEAS-2B cells 186 
exposed to micro-CoCrMo particles (Figure 2B), a significant reduction in viability (compared to 187 
control) was REVHUYHG DW  ȝJP/ DIWHU   DQG  KU RI H[SRVXUH DQG DW WKH KLJKHVW188 
FRQFHQWUDWLRQRIȝJP/DIWHU-48 hr of exposure. When comparing the toxicity of nano- and 189 
micro-CoCrMo under identical conditions, nano-CoCrMo caused significantly less toxicity than 190 
micro-CoCrMo in BEAS-%FHOOVDWȝJP/DIWHUDQGKURIH[SRVXUHDQGDWȝJP/191 
after 6 and 12 hr of exposure; toxicity was similar for ȝJP/nano- and micro-CoCrMo after 192 
24 and 48 hr of exposure. 193 
For osteoblasts (OB), cell viability remained high (> 90%) over the exposure periods tested 194 
(6-48 hr) for 0.1-ȝJP/QDQR- and micro-CoCrMo particles (Figure 2C). At 100 and 1000 195 
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ȝJP/DVLJQLILFDQWGHFUHDVHLQFHOOYLDELOLW\FRPSDUHGWRFRQWUROZDVREVHUYHGafter 6-48 hr 196 
exposure of nano- (Figure 2C) and micro-CoCrMo (Figure 2D) particles and the cell viability 197 
decreased with increasing exposure time. There were no significant differences in the toxicity of 198 
nano- and micro-CoCrMo particles over the concentration and exposure range studied, with the 199 
H[FHSWLRQ RI  ȝJP/, where nano-CoCrMo caused significantly less toxicity than micro-200 
CoCrMo in OB after 24 hr of exposure (~70 % vs. ~60 % remaining cell viability, respectively).  201 
In macrophages (M0), cell viability remained > 90% for the lowest concentrations of 0.1 202 
DQGȝJP/RYHUWKH-48 hr exposure period for both nano- and micro-CoCrMo (Figure 2). M0 203 
exposed to nano-CoCrMo had significantly reduced viability (compared to control) after 24 and 204 
KUH[SRVXUHWRȝJP/Figure 2E); no significant toxicity was observed between CoCrMo 205 
particles and controls at this concentration in either BEAS-2B or OB under these conditions. 206 
Significantly reduced cell viability was also observed for the micro-&R&U0RSDUWLFOHVDWȝJP/207 
after 48 hr of exposure (Figure 2F). 0RUHRYHUDWDQGȝJP/a significant decrease in 208 
cell viability (compared to control) was observed for both nano- and micro-CoCrMo particles at 209 
WKH WLPH H[SRVXUHV VWXGLHG H[FHSW DW  KU RI  ȝJP/ RI PLFUR-CoCrMo particles. When 210 
FRPSDUHGGLUHFWO\0YLDELOLW\DIWHUH[SRVXUHWRȝJP/QDQR-CoCrMo for 24 and 48 hr was 211 
significantly lower than M0 exposed to micro-CoCrMo particles under identical conditions. 212 
3.3.  CoCrMo Effects on Oxidative Stress: Oxidative stress was measured in the form of 213 
DCF/DHE fluorescence after exposure to nano- and micro-CoCrMo particles under identical 214 
exposure conditions tested in the viability assay. Compared to control, there was a significant 215 
increase in DCF fluorescence in BEAS-2B cells exposed to ȝJP/nano-CoCrMo after 6, 12 216 
and 24 hr of exposure and DWȝJP/DIWHU and 48 hr of exposure; a maximum 3.5 217 
fold increase in DCF fluorescence was observed in BEAS-2B FHOOVH[SRVHGWRȝJP/QDQo-218 
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CoCrMo after 6 hr of exposure, after which DCF fluorescence decreased with increasing exposure 219 
time (Figure 3A). In BEAS-2B cells exposed to micro-CoCrMo particles, a significant increase in 220 
DCF fluorescence was observed after 6 hr exposure to 10 and 100 ȝg/mL and after 6, 12, 24 and 221 
KUH[SRVXUHWRȝJP/PLFUR-CoCrMo; a maximum 2.3 fold increase in DCF fluorescence 222 
ZDVREVHUYHGLQFHOOVH[SRVHGWRȝJP/PLFUR-CoCrMo after 6 hr of exposure (Figure 3B). 223 
$WȝJP/RIERWKQDQR- and micro-CoCrMo particles, the DCF fluorescence decreased with 224 
increasing exposure time (Figure 3).  In addition, nano-CoCrMo particles caused a significantly 225 
greater change in DCF fluorescence compared to micro-CoCrMo particles after 6, 12 and 24 hr 226 
H[SRVXUHWRȝJP/DQGDIWHUDQGKUDWȝJP/Figure 3).  227 
For dihydroethidium (DHE), no significant differences, compared to control, were 228 
observed in BEAS-2B fluorescence after exposure to nano-CoCrMo (Figure 4A) or micro-229 
CoCrMo (Figure 4B) particles. The observed DHE fluorescence in BEAS-2B cells exposed to 230 
both nano- and micro-CoCrMo particles was about the same as the control cells at all 231 
concentrations (0.1-ȝJP/DQGH[SRVXUHWLPHV-48 hr) studied. 232 
 In osteoblasts (OB), nano-CoCrMo caused a significant increase in ¶¶-233 
dichlorofluorescein diacetate (DCF) fluorescence, compared to control, at 0.1 ȝJP/DIWHUKU234 
DWȝJP/ after 12 and 24 hr DQGDPD[LPXPLQFUHDVHLQ'&)IOXRUHVFHQFHDWȝJP/235 
after 24 hr of exposure, about 1.5-fold higher than control (Figure 5A). Exposure to micro-236 
CoCrMo caused significantly increased DCF fluorescence, compared to control, after 12 hr 237 
exposure to 0.1, 1DQGȝJP/DQGDIWHUKUH[SRVXUHWRȝJP/Figure 5B). 238 
Overall, nano-CoCrMo caused significantly higher DCF florescence than micro-CoCrMo in OB 239 
DIWHUKUH[SRVXUHWRDQGȝJP/ (Figure 5). 240 
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 A varied effect on dihydroethidium (DHE) fluorescence was observed in osteoblasts (OB) 241 
exposed to nano- and micro-CoCrMo particles (Figure 6). Compared to control, a significant 242 
increase in DHE fluorescence was observed in OB exposed to nano-&R&U0RDWȝJP/DIWHU243 
KUDWȝJP/DIWHU DQGKUDWȝJP/DIWHUDQGKUDWȝJP/DIWHU244 
DQGKU DQGDW ȝJP/DIWHU  DQGKURI H[SRVXUH Figure 6A). For micro-245 
CoCrMo particles, a significant increase in DHE, compared to control, was observed for 0.1-1000 246 
ȝJP/DIWHUKURIH[SRVXUHDQGIRUDQGȝJP/DIWHUKURIH[SRVXUHFigure 247 
6B). Compared to micro-CoCrMo, nano-CoCrMo caused significantly less DHE fluorescence at 248 
DQGȝJP/ after 6 hr and DWDQGȝJP/DIWHUKUKRZHYHUDWȝJP/QDQR-249 
CoCrMo caused significantly higher DHE fluorescence than micro-CoCrMo after 6, 24 and 48 hr 250 
of exposure (Figure 6A).   251 
 In macrophages (M0), nano- and micro-CoCrMo particles caused significant increases in 252 
¶¶-dichlorofluorescein diacetate (DCF) fluorescence, compared to control, at all concentrations 253 
(0.1-1000 ȝJP/ DQG H[SRVXUH WLPHV WHVWHG Figure 7). The maximum increase in DCF was 254 
REVHUYHGDWȝJP/DIWHUDQGKUH[SRVXUHFigure 7) for both nano- and micro-CoCrMo 255 
particles. Compared directly, nano-CoCrMo caused significantly less DCF fluorescence than 256 
micro-&R&U0RSDUWLFOHVDIWHUKUH[SRVXUHWRDQGȝJP/KRZHYHUQDQR-CoCrMo 257 
caused significantly higher DCF fluorescence than micro-CoCrMo after 6 and 12 hr exposure to 258 
ȝJP/DQGDIWHUDQGKUH[SRVXUHWRȝJP/Figure 7).  259 
 Significantly increased dihydroethidium (DHE) fluorescence, compared to control, was 260 
observed in macrophages (M0) exposed to nano-CoCrMo at all concentrations tested (0.1-1000 261 
ȝJP/DIWHUDQGKURIH[SRVXUHQRFKDQJHVLQ'+(ZHUHREVHUYHGDIWHUKURIH[SRVXUH262 
at any concentration (Figure 8A). In M0 exposed to micro-CoCrMo, a significant increase in DHE 263 
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fluorescence was observed after 6 and 12 hr exposure to 0.1-ȝJP/'+(OHYHOVZHUHVLPLODU264 
to control at all concentrations after 24 and 48 hr of exposure to micro-CoCrMo (Figure 8B). 265 
Compared to micro-CoCrMo, nano-CoCrMo caused significantly higher DHE levels in M0 at all 266 
concentrations (0.1-ȝJP/DIWHUDQGKURIH[SRVXUHFigure 8).  267 
 268 
4.  Discussion 269 
Nanoparticles, due to their smaller size, have a higher capacity (compared to 270 
microparticles) to enter the circulatory system and deposit in tissues and organs such as liver, 271 
spleen, kidney, lymph node and lung,3, 32-34 and the potential systemic effects of nanoparticle 272 
exposure could be of importance.35 However, the role of nanoparticles and microparticles from 273 
orthopaedic implant wear in systemic responses is unknown although patients who undergo 274 
CoCrMo joint replacements have presented translocation and deposition of CoCrMo wear particles 275 
in lymph nodes, liver and spleen.3, 36 Meanwhile, inhalation of cobalt-containing metal particles 276 
PD\EHDVVRFLDWHGZLWKGHQWDOWHFKQLFLDQ¶VSQHXPRFRQLRVLV,16, 17, 20, 37 and CoCrMo wear particles 277 
have also been a major concern of local toxicity and inflammation. Therefore, the goal of this study 278 
was to examine the toxic effects of nano- and micro-sized CoCrMo particles, originating from 279 
ASTM F75 orthopaedic implant materials, in a range of relevant cell types representing the 280 
potential routes of exposures, including lung epithelial cells, osteoblasts, and macrophages. 281 
Our studies suggest that both nano- and micro-CoCrMo particles can induce toxicity in all 282 
cell types studied and the responses of cell viability and oxidative stress are dose, exposure time 283 
and cell type specific. Across the three cell types tested, at low concentrations (i.e. 0.1 and 1 284 
ȝJP/QDQR- and micro-CoCrMo particles did not cause significant toxicity in our viability assay.  285 
Typically, in the presence of small amounts of foreign particles, cells may isolate the particles in 286 
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internal phagolysosomal compartments, which could prohibit them from further interacting with 287 
other cellular components thereby preventing extensive cellular toxicity.11, 38 The similarity in low 288 
toxicity between the nano- and micro-CoCrMo particles reported here in lung epithelial cells, 289 
osteoblasts and macrophages at concentrations less than  ȝJP/ VHHPV WR VXSSRUW WKH KLJK290 
biocompatibility of CoCrMo alloys in orthopaedic settings;39 CoCrMo has been used prevalently 291 
in orthopaedic surgeries.3 At high concentrations (i.e. 100 and 1000 µg/mL for BEAS-2B and OB 292 
cells, and 10, 100 and 1000 µg/mL for M0 cells), both nano- and micro-CoCrMo particles could 293 
lead to significant decreases in viability in all cell types tested. It was reported that significant 294 
toxicity was observed in osteoblast-OLNHFHOOVH[SRVHGWR ȝJP/PLFUR-CoCr alloy particles 295 
after 24 and 48 hr exposure.40 The current study provides direct evidence that nano- and micro-296 
CoCrMo particles cause toxicity toward lung epithelial cells in vitro; although lung epithelial cells 297 
are not a direct site of exposure in the case of orthopaedic joint wear, we speculate that these data 298 
may help explain the risk of lung disease in dental workers16, 17, 20, 37, 41, 42 and highlights the need 299 
for further examination of pulmonary toxicity caused by CoCrMo particles, whether exposure is 300 
due to inhalation (in the case of DTP) or tissue migration of implant wear particles to the lung.  301 
  One would normally expect that nanoparticles exert greater toxic effects than 302 
microparticles of the same chemical composition due to their smaller size and increased surface 303 
area.31, 33, 43-45 However, in this study, no significant differences in cell viability were observed 304 
between nano- and micro-CoCrMo particle exposures in most of the concentrations and exposure 305 
times studied. Interestingly, compared to micro-CoCrMo particles, nano-CoCrMo particles led to 306 
significantly lower viability of macrophages and significantly higher viability of lung epithelial 307 
cells and osteoblasts at 1000 µg/mL. In macrophages, it was believed that nanoparticles, due to 308 
their smaller size and thereby faster degradation at a given pH, could lead to more impairment in 309 
14 
 
phagocytosis and be more toxic to macrophages compared to microparticles.46-48 In this case, it 310 
possible that differences in the uptake of nano- and micro-CoCrMo could have contributed to the 311 
higher toxicity of nano-CoCrMo, as smaller particles may be more frequently and rapidly 312 
phagocytosed compared to the larger micro-CoCrMo particles. It is not clear why nano-CoCrMo 313 
was less toxic, compared to micro-CoCrMo, to lung epithelial cells and osteoblasts in this study 314 
and further investigations are much needed. 315 
Oxidative stress has been implicated in age-related bone resorption and osteoporosis49 and 316 
in toxicity of CoCrMo particles in fibroblasts,50-52 and may also play a role in the progression of 317 
lung diseases,53 such as those caused by cobalt-containing metal exposures.54 Therefore, it is 318 
important to examine the capacity of nano- and micro-CoCrMo particles in causing oxidative stress 319 
in our cell models. In this case, we used a two-fold approach to assess the induction of oxidative 320 
VWUHVVXVLQJ'&)ZKLFKVHUYHVDVDµJHQHUDOL]HG¶PDUker for reactive oxygen species,55 and DHE, 321 
which serves as a specific marker of superoxide anion.56 It seems that the oxidative responses 322 
against nano- and micro-CoCrMo particles were cell specific: both nano- and micro-CoCrMo 323 
particles resulted in significantly higher DCF levels and DHE levels in OB and M0 cells; 324 
significantly higher DCF and DHE levels were observed in macrophages at all concentrations 325 
studied (0.1-1000 µg/mL). It seems that the OB cells behaved like the M0 immune cells, which 326 
DUHNQRZQWRH[KLELWD³UHVSLUDWRU\EXUVW´XSRQSKDJRF\WRVLVRIPLFUREHV, marked by significant 327 
increases in the production of hydrogen peroxide and superoxide anion via enzymatic pathways 328 
that are critical for initiating anti-microbial response and infection clearance.57 Meanwhile, 329 
corrosion of metal in aqueous environment could contribute to oxidative stress. Low levels (e.g. 330 
0.02 µg/mL) of Mo, Co, and Cr ions have been detected in CoCrMo particle solutions after short 331 
time exposures (e.g. 24 hr),58 and substantial evidence has indicated that metals and metal ions, 332 
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including Co and Cr, cause oxidative stress in situ regardless of the means of exposure.5, 7 In this 333 
study, the oxidative stress was likely attributed to the combined effects of nanoparticle exposure 334 
and the ions released. 335 
The significantly increased oxidative stress of osteoblasts (OB) and macrophage (M0) cells 336 
may help explain the increased risks of implant loosening and osteolysis in orthopaedic implant 337 
patients,4-7 as there is evidence suggesting that the presence of wear particles in the joint fluid 338 
stimulates a localized inflammatory response.4 Localized inflammation promotes osteoclast 339 
activity, bone resorption and loosening of the implant.59 By contrast, BEAS-2B cells had no 340 
significant DHE changes but had significantly increased DCF levels at relatively high particle 341 
concentrations (e.g. 100 and 1000 µg/mL). Moreover, nano-CoCrMo caused significantly higher 342 
levels of oxidative stress in lung epithelial cells compared to micro-CoCrMo particles at 343 
concentrations of 100 and 1000 ȝJP/ZKLFKwas consistent with the expected size-dependent 344 
effect due to the increased reactive surface area of nano-CoCrMo compared to micro-CoCrMo. 345 
No significant differences were found in the DHE assay, which suggests that CoCrMo particles 346 
cause oxidative stress via other species than superoxide anion. Additionally, we found these results 347 
were consistent with the fibroblast studies in the literature,51, 60 which found high levels of 348 
oxidative stress, marked by increased levels of DCF fluorescence, after as little as 2 hr of 349 
exposure60 and increased levels of 8-OHdG staining, a marker of oxidative stress induced DNA 350 
damage, after 24 hr of exposure to CoCrMo particles.51 Increased levels of oxidative stress in lung 351 
epithelial cells could ultimately lead to downstream effects such as DNA damage and genotoxicity 352 
upon long term exposure11, 51, 61 and may therefore be a contributing factor in the development of 353 
lung disease from pulmonary CoCrMo particle exposure in occupational settings. 354 
 355 
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5.  Conclusions 356 
 This study examined the toxicity of nano- and micro-CoCrMo particles and determined 357 
whether their exposure induced oxidative stress in human lung epithelial cells, osteoblasts and 358 
macrophages. These in vitro findings suggest that both nano- and micro-CoCrMo particles can 359 
induce toxicity and the responses of cell viability and oxidative stress are dose, exposure time and 360 
cell type specific. In future studies, the mechanism of cellular uptake and the cellular distribution 361 
and excretion of CoCrMo particles will be investigated. The toxicity of these particles will be 362 
further examined in animal models which generally provides a better approximation of what may 363 
occur during a real-life exposure situation. For instance, CoCrMo nanoparticles may be injected 364 
in a bone implant rat model62-64 or exposed to the lung in an intra-tracheal instillation rat model65 365 
to examine their local and systemic toxicity. 366 
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LIST OF ABBREIVIATED TERMS 378 
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ATCC: American Type Tissue Collection 379 
CoCrMo: cobalt chromium molybdenum 380 
'&)¶¶-dichlorofluorescein diacetate 381 
DHE: dihydroethidium 382 
DLS: dynamic light scattering 383 
'0(0'XOEHFFR¶V0RGLILHG(DJOH0HGLD 384 
'73GHQWDOWHFKQLFLDQ¶VSQHXPRFRQLRVLV 385 
EDTA: ethylenediaminetetraacetic acid 386 
FBS: fetal bovine serum 387 
HMLD: hard metal lung disease 388 
micro-CoCrMo: CoCrMo microparticles 389 
nano-CoCrMo: CoCrMo nanoparticles 390 
OB: osteoblast 391 
PBS: phosphate buffered saline 392 
PMA: phorbol-12-mystirate-13-acetate 393 
SEM: scanning electron microscope 394 
TEM: transmission electron microscopy 395 
WC-Co: tungsten carbide cobalt 396 
 397 
  398 
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FIGURE AND TABLE LEGEND 399 
 400 
Figure 1. A,B) Images and C,D) particle size distribution of A,C) nano- and B, D) micro-CoCrMo 401 
particles.  402 
Figure 2. Viability of (A, B) BEAS-2B lung epithelial cells, (C, D) osteoblasts, and (E, F) 403 
macrophages after exposure to (A, C, E) nano- and (B, D, F) micro-CoCrMo particles. (*P < 0.05, 404 
?P < 0.01 compared to control; ?P < 0.05 vs. micro-CoCrMo)  405 
Figure 3. BEAS-2B oxidative stress measured via fluorescence intensity of DCF after exposure 406 
to A) nano- and B) micro-CoCrMo particles. (*P < 0.05, ?P < 0.01 compared to control; ?P < 0.05 407 
vs. micro-CoCrMo) 408 
Figure 4. BEAS-2B oxidative stress measured via fluorescence intensity of DHE after exposure 409 
to A) nano- and B) micro-CoCrMo particles. (*P < 0.05, ?P < 0.01 compared to control; ?P < 0.05 410 
vs. micro-CoCrMo) 411 
Figure 5. Osteoblast oxidative stress measured via fluorescence intensity of DCF after exposure 412 
to A) nano- and B) micro-CoCrMo particles. (*P < 0.05, ?P < 0.01 compared to control; ?P < 0.05 413 
vs. micro-CoCrMo) 414 
Figure 6. Osteoblast oxidative stress measured via fluorescence intensity of DHE after exposure 415 
to A) nano- and B) micro-CoCrMo particles. (*P < 0.05, ?P < 0.01 compared to control; ?P < 0.05 416 
vs. micro-CoCrMo) 417 
Figure 7. Macrophage oxidative stress measured via fluorescence intensity of DCF after exposure 418 
to A) nano- and B) micro-CoCrMo particles. (*P < 0.05, ?P < 0.01 compared to control; ?P < 0.05 419 
vs. micro-CoCrMo) 420 
Figure 8. Macrophage oxidative stress measured via fluorescence intensity of DHE after exposure 421 
to A) nano- and B) micro-CoCrMo particles. (*P < 0.05, ?P < 0.01 compared to control; ?P < 0.05 422 
vs. micro-CoCrMo)  423 
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